Opipramol

Research use only, not for human use.

Opipramol (Ensidon) is a compound with antidepressant activity that attenuates cocaine-seeking behavior in a rat model of self-administration.

Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA). Opipramol acts primarily as a sigma (σ) receptor agonist and can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol can be used for the research of generalized anxiety disorder (GAD).

Opipramol can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol inhibit the uptake of [3H] DA in crude synaptosomal preparations with an IC50 value of 5.5 μM.

Opipramol (i.p.; 5-50 mg/kg) increases dopamine release in vivo.Animal Model:Sprague-Dawley rats (male, 150-l 80 g) Dosage:5-50 mg/kg Administration:Intraperitoneal injections Result:Increased the levels of DOPAC and HVA in the striatum of the rat, without changing the steady-state levels of DA.Potently increased the metabolism of dopamine in the striatum, olfactory tubercle and pyriform cortex of the rat.Increased plasma prolactin in the rat, only at a dose as large as 50 mg/kg dose.

——

Autophagy

Sigma receptor

Sigma receptor

——

——

315-72-0

363.5

C23H29N3O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (275.10 mM; Ultrasonic )

OCCN1CCN(CC1)CCCN2C=3C=CC=CC3C=CC=4C=CC=CC42

——

(-20℃)

With Ice Pack

≥ 2 years